All CIS patients were treatment naïve while 4/12 RRMS patients were on immunomodulatory treatment (3 received IFNb and 1 copolymer acetate) while 3/12 SPMS patients were treated with IFNb. The gene discussed is IFNB1; the disease is in situ carcinoma.